Covid Vaccine Race

European Medicines Agency exercises its option for increasing the confirmed order commitment by 80 million doses, bringing total to 160 million.

Allergists offer risk stratification approach to avoid rare allergic reaction to COVID-19 vaccines

The US and the world must appreciate the role of the pharmaceutical industry—the investigators, physicians and business leaders—who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.

In the first week of 2021, the US is currently leading all countries in total vaccine administrations, despite state-level distribution setbacks.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

Though regulatory authorization has not been granted, the company intends to vaccinate up to 50 million people prior to the Lunar New Year.

The authorization recommends dosage intervals of between 4 and 12 weeks.

Trial to enroll up to 30000 volunteers across approximately 115 sites in the US and Mexico.

With the public beginning to get vaccinated, CDC published information for people in some medical categories and considerations on severe allergic reactions.

Vaccine manufacturer Valneva recently announced it was initiating a phase 1/2 trial in the United Kingdom.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

At the interim analysis, the mRNA-1273 vaccine was found to have an efficacy of 94.5% against confirmed COVID-19.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.

Covaxx CEO Mei Mei Hu has seen vaccines from development all the way through to government approval. She offers her unique perspective into vaccine creation and an update on her company’s COVID-19 vaccine.

Data from three ongoing clinical studies were included in the EUA request.

The country's first authorized vaccine will be first available to healthcare workers and long-term care residents.

The VRBPAC committee voted 17-4, with 1 abstention, to support the benefit-risk profile of BNT162b2 for preventing COVID-19 in persons aged 16 years and older.

Pending investigations of 2 severe adverse events, people with a history of severe allergies are being advised by the UK’s regulatory agency not to get vaccinated.

Just one day before the FDA meeting to discuss potential US authorization of the Pfizer and BioNtech vaccine, that country approves the vaccine.

The first COVID-19 vaccines in the US will be from the unique platform. An expert explains how they work.

The announcement follows Pfizer and Moderna who both showed their vaccines to be over 90% efficacious.

Public understanding of adverse events could be an obstacle in the rollout of vaccines to fight the coronavirus disease 2019 (COVID-19).

The primary outcome was to determine how many cases of symptomatic COVID-19 disease there were in participants who had received two doses of the vaccine.

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

The study was posted to the website clinicaltrials.gov this past Wednesday.

Authorization for a COVID-19 vaccine in the US appears imminent, bringing with it a host of concerns including the speed of development, inclusivity of clinical trials, safety of mRNA technology, and how to raise levels of trust in vulnerable populations.